Wegovy Articles Worth Reading — and What They Often Get Wrong

The myth that Wegovy 'does the work for you', and what the trials really measured

The most persistent misconception in Wegovy articles is that semaglutide produces weight loss on its own. Every significant trial (including STEP 1, published in the New England Journal of Medicine) enrolled participants who also followed a reduced-calorie diet and increased their physical activity alongside the medicine. The ~15% average weight reduction at 2.4mg was measured in that context. The medicine reduces appetite and slows how quickly the stomach empties, making it considerably easier to sustain a calorie deficit, but the lifestyle component is part of the licensed framework, not an optional extra.

This distinction matters for setting expectations. People who read coverage of Wegovy and expect the pen alone to deliver those results may be disappointed when progress requires consistent effort alongside it. Our prescribers hear a version of this question most weeks, patients arrive having read about the trial figures and wonder why their experience feels harder than the headlines suggested. The honest answer is that the trials were designed with wraparound support; the medicine is a powerful tool, not a passive one.

A second common error in press coverage is conflating Wegovy with Ozempic. Both contain semaglutide, but Ozempic is licensed for type 2 diabetes in the UK, not weight management. They are not interchangeable, and anyone seeking a weight-loss prescription should be asking about Wegovy specifically, or exploring how semaglutide works as a weight-loss medicine in its licensed form.

The 7.2mg dose: what the recent approvals actually mean for patients

Since early 2026, Wegovy coverage has centred on the higher 7.2mg maintenance dose. The MHRA approved this dose in January 2026, initially available as three 2.4mg pens used weekly. A dedicated single-dose 7.2mg pen (one pre-set injection per week, with a built-in covered needle that locks after use) received MHRA approval on 14 April 2026, as confirmed in GOV.UK's announcement. Trials at this dose reported around 20.7% average weight loss over 72 weeks, which approaches results seen with tirzepatide at its highest dose.

What many articles have glossed over: the 7.2mg approval applies to adults with a BMI of 30 or above only. It is not indicated for the cardiovascular-risk reduction purpose, and the dose pathway still begins at 0.25mg, titrated upward by a prescriber over several months. Jumping to the headline figure without reading the patient selection criteria has led to some misleading comparisons circulating online. The starting dose exists to help your system adjust gradually, which is why titration is prescriber-led rather than self-directed.

If you are considering beginning treatment, what matters is not the theoretical ceiling dose but the dose a prescriber considers appropriate for you at each stage, based on how you are responding and tolerating the medicine.

Side effects: what good Wegovy articles include, and what some skip over

Responsible coverage of semaglutide always addresses side effects. The profile is dominated by gastrointestinal effects: nausea tends to be the most frequently mentioned, alongside loose stools, constipation, indigestion and fatigue. These are most pronounced when starting or after a dose increase, and typically settle within days to a couple of weeks for most people. Articles that gloss over this (or that frame it as rare) are not giving readers a fair account.

Less commonly covered, but worth knowing: some people experience muscle discomfort during treatment, and if you are wondering whether Wegovy can make your muscles hurt, our dedicated page explains what drives this and is worth reading before you start.

In January 2026, the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious side effect across GLP-1 medicines. The symptom to act on quickly is severe, persistent stomach pain that may radiate to the back, with or without vomiting. That warrants urgent medical attention. Patients and healthcare professionals can report suspected side effects through the Yellow Card scheme. Any article that covers Wegovy comprehensively should mention this; consider the absence of it a gap in the coverage.

NHS access, private routes, and what the eligibility criteria genuinely are

A lot of Wegovy articles treat NHS access as either freely available or entirely out of reach. The real picture sits somewhere in between. NICE recommends semaglutide (TA875) for adults with a BMI of 35 or above and at least one weight-related condition, used for a maximum of two years within a specialist weight management service. NHS waiting lists for those services are commonly long. Eligibility thresholds are generally 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

For people who meet the licensed criteria but are not on an NHS pathway, private treatment through a GPhC-registered pharmacy is the regulated alternative. There is no referral required and no waiting list. A prescriber still needs to review your medical history, current medicines and BMI before a prescription is issued, that step is not optional regardless of how you access it. If you want to understand what the assessment involves and what it costs, our Wegovy price comparison page walks through what legitimate private pricing typically includes.

Anyone considering treatment can also read our overview of weight-loss treatment options before committing to a consultation. Getting the right medicine for your situation is more important than getting any medicine quickly. When you feel ready to take the next step, you can start your free consultation with our clinical team.